Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6456 USD | -0.53% | +1.51% | -13.41% |
May. 07 | Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy | CI |
Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
Financials (USD)
Sales 2024 * | 210K | Sales 2025 * | 300K | Capitalization | 13.61M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -28M | EV / Sales 2024 * | 64.8 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 45.4 x |
P/E ratio 2024 * |
-0.75
x | P/E ratio 2025 * |
-0.78
x | Employees | 18 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.39% |
Latest transcript on Traws Pharma, Inc.
1 day | -0.53% | ||
1 week | +1.51% | ||
Current month | -2.18% | ||
1 month | -18.79% | ||
3 months | -7.11% | ||
6 months | +0.88% | ||
Current year | -13.41% |
Managers | Title | Age | Since |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 15-01-18 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 13-08-31 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 15-06-30 |
Jack Stover
BRD | Director/Board Member | 69 | 16-05-22 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 20-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 0.6456 | -0.53% | 32,910 |
24-05-09 | 0.649 | -0.21% | 55,748 |
24-05-08 | 0.6504 | -1.99% | 35,637 |
24-05-07 | 0.6636 | +3.53% | 53,229 |
24-05-06 | 0.641 | +0.79% | 45,468 |
Delayed Quote Nasdaq, May 10, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.41% | 13.61M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- TRAW Stock